Literature DB >> 2861102

Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine.

G Gianutsos, S Chute, J P Dunn.   

Abstract

The pharmacological effects of 6 weeks administration of amantadine was evaluated in the mouse. Motor stimulation induced by amphetamine or the amantadine analog memantine was reduced while that of apomorphine was enhanced by the long-term amantadine treatment. This was accompanied by an increase in the binding of spiroperidol to putative striatal dopamine receptors, without a change in amantadine-induced inhibition of dopamine uptake in the striatum. The possible significance of changes in pre- and postsynaptic dopamine mechanisms is discussed in relation to the anti-parkinson activity of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861102     DOI: 10.1016/0014-2999(85)90564-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  Managing antipsychotic-induced parkinsonism.

Authors:  D C Mamo; R A Sweet; M S Keshavan
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 3.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

4.  Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats.

Authors:  Samuel S Shin; Eric R Bray; Cathy Q Zhang; C Edward Dixon
Journal:  Brain Res       Date:  2010-11-01       Impact factor: 3.252

Review 5.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 6.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

7.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

8.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 9.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.